Page 122 - 《中国药房》2023年20期

guidelines in oncology[J]. J Natl Compr Canc Netw， emtansine versus treatment of physician’s choice in
2022，20（6）：691-722. patients with previously treated HER2-positive metastatic
[ 4 ] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会 breast cancer（TH3RESA）：final overall survival results
（CSCO）乳腺癌诊疗指南：2023[M]. 北京：人民卫生出版 from a randomised open-label phase 3 trial[J]. Lancet
社，2023：1-210. Oncol，2017，18（6）：743-754.
Guidelines Working Committee of the Chinese Clinical [16] PEREZ E A，BARRIOS C，EIERMANN W，et al. Trastu‐
Oncology Society. Guidelines of Chinese Society of Clini‐ zumab emtansine with or without pertuzumab versus
cal Oncology（CSCO）：breast cancer 2023[M]. Beijing： trastuzumab with taxane for human epidermal growth
People’s Health Publishing House，2023：1-210. factor receptor 2-positive advanced breast cancer：final
[ 5 ] CORTÉS J，KIM S B，CHUNG W P，et al. Trastuzumab results from MARIANNE[J]. Cancer，2019，125（22）：
deruxtecan versus trastuzumab emtansine for breast cancer 3974-3984.
[J]. N Engl J Med，2022，386（12）：1143-1154. [17] XU Z Y，GUO D D，JIANG Z L，et al. Novel HER2-tar‐
[ 6 ] BARDIA A，TOLANEY S M，LOIRAT D，et al. LBA17 geting antibody-drug conjugates of trastuzumab beyond
ASCENT：a randomized phase Ⅲ study of sacituzumab T-DM1 in breast cancer：trastuzumab deruxtecan（DS-
govitecan（SG） vs treatment of physician’s choice（TPC） 8201a）and （vic-）trastuzumab duocarmazine（SYD985）
in patients（pts）with previously treated metastatic triple- [J]. Eur J Med Chem，2019，183：111682.
negative breast cancer（mTNBC）[J]. Ann Oncol，2020， [18] SHARKEY R M，MCBRIDE W J，CARDILLO T M，et
31：S1149-S1150. al. Enhanced delivery of SN-38 to human tumor xeno‐
[ 7 ] BARDIA A，MAYER I A，VAHDAT L T，et al. Sacitu‐ grafts with an anti-trop-2-SN-38 antibody conjugate（saci‐
zumab govitecan-hziy in refractory metastatic triple- tuzumab govitecan）[J]. Clin Cancer Res，2015，21（22）：
negative breast cancer[J]. N Engl J Med，2019，380（8）： 5131-5138.
741-751. [19] VERMA S，MILES D，GIANNI L，et al. Trastuzumab
[ 8 ] The Cochrane Collbration. Cochrane handbook for sys‐ emtansine for HER2-positive advanced breast cancer[J].
tematic reviews of interventions，version 5.1.0[EB/OL]. N Engl J Med，2012，367（19）：1783-1791.
[2023-03-15]. http：//handbook-5-1.cochrane.org/. [20] MODI，PARK H，MURTHY R K，et al. Antitumor activity
[ 9 ] RUGO H S，BARDIA A，MARMÉ F，et al. Sacituzumab and safety of trastuzumab deruxtecan in patients with
govitecan in hormone receptor-positive/human epidermal HER2-low-expressing advanced breast cancer：results
growth factor receptor 2-negative metastatic breast cancer from a phase Ⅰ b study[J]. J Clin Oncol，2020，38（17）：
[J]. J Clin Oncol，2022，40（29）：3365-3376. 1887-1896.
[10] BARDIA A，HURVITZ S A，TOLANEY S M，et al. Saci‐ [21] BARDIA A，MAYER I A，DIAMOND J R，et al. Efficacy
tuzumab govitecan in metastatic triple-negative breast can‐ and safety of anti-trop-2 antibody drug conjugate sacitu‐
cer[J]. N Engl J Med，2021，384（16）：1529-1541. zumab govitecan （IMMU-132） in heavily pretreated
[11] HURVITZ S A，DIRIX L，KOCSIS J，et al. Phase Ⅱ ran‐ patients with metastatic triple-negative breast cancer[J]. J
domized study of trastuzumab emtansine versus trastu‐ Clin Oncol，2017，35（19）：2141-2148.
zumab plus docetaxel in patients with human epidermal [22] KUNST N，WANG S Y，HOOD A，et al. Cost-effective-
growth factor receptor 2-positive metastatic breast cancer ness of neoadjuvant-adjuvant treatment strategies for women
[J]. J Clin Oncol，2013，31（9）：1157-1163. with ERBB2（HER2）-positive breast cancer[J]. JAMA
[12] MODI S N，JACOT W，YAMASHITA T，et al. Trastu‐ Netw Open，2020，3（11）：e2027074.
zumab deruxtecan in previously treated HER2-low advanced [23] MASTERS J C，NICKENS D J，XUAN D W，et al. Clini‐
breast cancer[J]. N Engl J Med，2022，387（1）：9-20. cal toxicity of antibody drug conjugates：a meta-analysis
[13] DIÉRAS V，MILES D，VERMA S，et al. Trastuzumab of payloads[J]. Invest New Drugs，2018，36（1）：121-135.
emtansine versus capecitabine plus lapatinib in patients [24] ZHANG L Y，SHEN D Y，YU L L，et al. Is antibody-drug
with previously treated HER2-positive advanced breast conjugate a rising star for clinical treatment of solid
cancer（EMILIA）：a descriptive analysis of final overall tumors? A systematic review and meta-analysis[J]. Crit Rev
survival results from a randomised，open-label，phase 3 Oncol Hematol，2022，177：103758.
trial[J]. Lancet Oncol，2017，18（6）：732-742. [25] YAN H H，ENDO Y，SHEN Y，et al. Ado-trastuzumab
[14] VON MINCKWITZ G，HUANG C S，MANO M S，et al. emtansine targets hepatocytes via human epidermal
Trastuzumab emtansine for residual invasive HER2-posi‐ growth factor receptor 2 to induce hepatotoxicity[J]. Mol
tive breast cancer[J]. N Engl J Med，2019，380（7）： Cancer Ther，2016，15（3）：480-490.
617-628. （收稿日期：2023-03-16 修回日期：2023-09-18）
[15] KROP I E，KIM S B，MARTIN A G，et al. Trastuzumab （编辑：陈 宏）

· 2544 · China Pharmacy 2023 Vol. 34 No. 20 中国药房 2023年第34卷第20期